摘要
目的:研究中药沐足方、加巴喷丁联合治疗糖尿病痛性神经病变(PDPN)的疗效及安全性。方法:将92例PDPN病例分为单纯加巴喷丁组和中药沐足方联合组各46例,在临床常规治疗的基础上,两组分别行加巴喷丁单纯治疗、加巴喷丁联合中药沐足方治疗。结果:中药沐足方联合组共91.30%的患者获得有效治疗,高于单纯加巴喷丁组的76.09%(P<0.05);治疗后,中药沐足方联合组患者正中神经、腓总神经MCV、SCV均大于单纯加巴喷丁组(P<0.05);单纯加巴喷丁组10.87%的患者有不适症状,与中药沐足方联合组的13.04%比较,差异无统计学意义(P>0.05)。结论:中药沐足方、加巴喷丁联合治疗PDPN的临床疗效显著,能有效改善患者的神经传导速度,且安全性良好,值得临床推广应用。
Objective:To study the efficacy and safety of Muzufang and gabapentin in the treatment of diabetic painful neuropathy(PDPN).Methods:92 cases of PDPN were divided into simple gabapentin group(46 cases)and Muzufang combined group(46 cases).On the basis of clinical routine treatment,the two groups were treated with gabapentin alone,and gabapentin combined with traditional Chinese medicine Muzufang treatment respectively.Results:91.30% of the patients in the Muzufang combined group received effective treatment,which was higher than 76.09% in the simple gabapentin group(P<0.05).After treatment,MCV and SCV of median nerve and common peroneal nerve in Muzufang combined group were higher than those in simple gabapentin group(P<0.05).There was no significant difference in symptoms of discomfort between the simple gabapentin group and Muzufang combined group(10.87%vs 13.04%,P>0.05).Conclusion:The clinical effect of Muzufang and gabapentin in the treatment of PDPN is significant,which can effectively improve the nerve conduction velocity of patients,and has good safety,which is worthy of clinical promotion and application.
作者
彭俊祥
龙可
何慧明
Peng Junxiang;Long Ke;He Huiming(Guangzhou Panyu Hospital of Chinese Medicine,Guangzhou,Guangdong 511400)
出处
《数理医药学杂志》
CAS
2021年第6期890-892,共3页
Journal of Mathematical Medicine
